Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8641180 | 0.96 | PLA2G1B (0.42) | KDM4EMAPK1TDP1PLA2G1BPLA2G2A | |
| SCHEMBL11211847 | 0.88 | L3MBTL1 (0.34) | L3MBTL1KDM4EMAPK1TDP1PLA2G1B | |
| SCHEMBL17615502 | 0.87 | KDM4E (0.35) | L3MBTL1KDM4EMAPK1TDP1PLA2G1B | |
| SCHEMBL11699005 | 0.87 | KDM4E (0.45) | KDM4EMAPK1TDP1PLA2G1BPLA2G2A | |
| SCHEMBL17199810 | 0.87 | GPR84 (0.47) | L3MBTL1PLA2G1BPLA2G2AGPR84 | |
| SCHEMBL3536738 | 0.86 | KDM4E (0.47) | L3MBTL1KDM4EMAPK1TDP1PLA2G1B | |
| SCHEMBL12469261 | 0.86 | FFAR1 (0.43) | MEN1KMT2A | |
| SCHEMBL17615501 | 0.85 | DNM1 (0.38) | L3MBTL1KDM4EMAPK1TDP1MEN1 | |
| SCHEMBL17615498 | 0.84 | KDM4E (0.34) | L3MBTL1KDM4EMAPK1TDP1MEN1 | |
| SCHEMBL1354800 | 0.83 | L3MBTL1 (0.36) | L3MBTL1KDM4EMAPK1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | SYNOVO GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | BURNET MICHEAL W (DE) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131943-A1 | ANTI-INFECTIVE AND ANTI-VIRAL COMPOUNDS AND COMPOSITIONS | CTSA, GAA, SLC7A5 | L3MBTL1 1536/4885KDM4E 3394/4885MAPK1 3989/4885 |
| US-20230159581-A1 | NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS | CTSA, ALOX15, ALOX5 | L3MBTL1 1562/4885KDM4E 3648/4885MAPK1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.